{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-049796","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.939128+00:00","generated_at":"2026-06-10T08:38:53.343619+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acasti Pharma closes $7.5M private placement for GTX-104 development","bullets":["Closed private placement on Sept 25, 2023: 1.95M common shares at $1.848 each, pre-funded warrants for 2.11M shares, and common warrants for 2.54M shares at $3.003 exercise.","Gross proceeds ~$7.5M, net ~$7.3M after fees; related parties (Shore Pharma, SS Pharma) participated.","Proceeds intended for GTX-104 Phase 3 trial, pre-commercial planning, working capital, and general corporate purposes.","Common warrants expire on the earlier of 60 days after FDA NDA acceptance for GTX-104 or 5 years from issuance.","Company to file resale registration statement within 30 days; failure may trigger liquidated damages."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-049796","json":"https://secwatch.observer/filing/0000950170-23-049796.json","markdown":"https://secwatch.observer/filing/0000950170-23-049796.md","text":"https://secwatch.observer/filing/0000950170-23-049796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/0000950170-23-049796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/acst-20230924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:38:53.343619+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59fab10891e0e0f62c6bb9ab4604821887683aa1","claim":"Grace Therapeutics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $7.3 million (effective 2023-09-24).","evidence_excerpt":"On September 24, 2023, Acasti Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors in connection with a private placement offering of the Company's securities (the “Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017023049796/0000950170-23-049796-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $7.3 million"},{"label":"Effective","value":"2023-09-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}